⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL875517 | 0.96 | — | — | |
| SCHEMBL3951285 | 0.88 | — | — | |
| SCHEMBL15847948 | 0.75 | — | — | |
| SCHEMBL6537258 | 0.68 | — | — | |
| SCHEMBL28739744 | 0.67 | — | — | |
| SCHEMBL28170742 | 0.66 | — | — | |
| SCHEMBL30629015 | 0.66 | — | — | |
| SCHEMBL126608 | 0.66 | — | — | |
| SCHEMBL29930619 | 0.66 | — | — | |
| SCHEMBL23174816 | 0.65 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3713916-A1 | 3,5-DIARYLIDENYL-N-SUBSTITUTED-PIPERID-4-ONE-DERIVED INHIBITORS OF STAT3 PATHWAY ACITIVTY AND USES THEROF | Kiakos, Konstantinos (AT) | 2020-09-30 | — | — | EP | disclosed |
| EP-3139921-A1 | BENZOMORPHAN ANALOGS AND USE THEREOF | Purdue Pharma L.P. (US) | 2017-03-15 | — | — | EP | disclosed |
| WO-2015171553-A1 | BENZOMORPHAN ANALOGS AND USE THEREOF | PURDUE PHARMA L.P. (US) | 2015-11-12 | — | — | WO | disclosed |
| WO-2014102592-A2 | OXIME/SUBSTITUTED QUINOXALINE-TYPE PIPERIDINE COMPOUNDS AND USES THEREOF | PURDUE PHARMA L.P. (US) | 2014-07-03 | — | — | WO | disclosed |
| EP-2076506-A2 | HETEROCYCLIC-SUBSTITUTED PIPERIDINES AS ORL-1 LIGANDS | Purdue Pharma L.P. (US) | 2009-07-08 | — | — | EP | disclosed |
| WO-2008089201-A2 | HETEROCYCLIC-SUBSTITUTED PIPERIDINE AS ORL-1 LIGANDS | PURDUE PHARMA L.P. (US) | 2008-07-24 | — | — | WO | disclosed |